Last reviewed · How we verify
NCT06814548
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
trial testing ICIs(Immune checkpoint inhibitors) in Gastric Cancer, Gastroesophageal Junction Cancer in 200 participants. Not yet recruiting.
31 May 2025
Quick facts
| Lead sponsor | Yongxu Jia |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 10 February 2025 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2025 |
Drugs / interventions tested
- ICIs(Immune checkpoint inhibitors) — full drug profile →
Conditions studied
- Gastric Cancer, Gastroesophageal Junction Cancer — all drugs for Gastric Cancer, Gastroesophageal Junction Cancer →
- Immune Checkpoint Inhibitors (ICIs) — all drugs for Immune Checkpoint Inhibitors (ICIs) →
- Second-line — all drugs for Second-line →
- Retreatment — all drugs for Retreatment →
Sponsor
Yongxu Jia — full company profile →
Who can join
18 and older, any sex, with Gastric Cancer, Gastroesophageal Junction Cancer or Immune Checkpoint Inhibitors (ICIs). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7
Verify or expand the search:
- PubMed search for NCT06814548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ICIs(Immune checkpoint inhibitors)
Trials testing the same drug.
- NCT06413017 — Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure · Phase 2 · recruiting
Other recruiting trials for Gastric Cancer, Gastroesophageal Junction Cancer
Currently open trials in the same condition.
- NCT06791538 — Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer · NA · recruiting
- NCT06760858 — A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer · recruiting
- NCT06786169 — The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer · recruiting
- NCT06640153 — MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma · active not recruiting
- NCT06662110 — IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer · recruiting
Other Yongxu Jia trials
Trials by the same sponsor.
- NCT06923020 — Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Can · enrolling by invitation
- NCT06939452 — A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-lin · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06814548 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yongxu Jia
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing